

July 22, 2020

Department of Corporate Services Bombay Stock Exchange Ltd. Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai- 400 001 Mr. Hari K Asst. Vice President - Operations National Stock Exchange of India Ltd Exchange Plaza, Bandra – Kurla Complex Bandra (East), Mumbai – 400 051

Ref: BSE Scrip Code -506690: NSE Symbol – UNICHEMLAB

Subject: Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith the press release pertaining to receipt of ANDA approval from United States Food and Drug Administration (USFDA) for Unichem's Amiodarone Tablets, USP 200 mg.

Thanking you,

For UNICHEM LABORATORIES LIMITED,

PRADEEP BHANDARI Head- Legal & Company Secretary



Registered Office: Unichem Bhavan, Prabhat Estate, Off S. V. Road Jogeshwari (West), Mumbai – 400 102, Maharashtra, India. Tel.: +91 (22) 66888333 • Fax.: +91 (22) 26784391 • Website: www.unichemlabs.com • CIN: L99999MH1962PLC012451



Mumbai, Wednesday, July 22, 2020

PRESS RELEASE

Unichem Laboratories Limited is pleased to announce that it has received ANDA approval for its Amiodarone Tablets, USP, 200 mg from the United States Food and Drug Administration (USFDA) to market a generic version of CORDARONE[®] (amiodarone) tablets of Wyeth Pharmaceuticals Inc.

Amiodarone tablets are indicated for the treatment of documented, life-threatening recurrent ventricular fibrillation and life-threatening recurrent hemodynamically unstable tachycardia in adults who have not responded to adequate doses of other available antiarrhythmics or when alternative agents cannot be tolerated. The product will be commercialized from Unichem's Ghaziabad Plant.

About Unichem Laboratories Limited

Unichem Laboratories Limited is an international, integrated, specialty pharmaceutical company. It manufactures and markets a large basket of pharmaceutical formulations as branded generics as well as generics in several markets across the world. In India, The Company has strong skills in product development, process chemistry and manufacturing complex API as well as dosage forms. More information about the Company can be found at <u>www.unichemlabs.com</u>

For more information please contact:

Mr. Pradeep Bhandari Ph: +91-22-66888 404 E-mail: pradeep.bhandari@unichemlabs.com

Disclaimer:

This press release includes forward-looking statements. We have based these forward-looking statements on our current expectations and projections about future events. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results to differ serially. Such factors include, but are not limited to, changes in local and global economic conditions, our ability to successfully implement our strategy, the market acceptance of and demand for our products, our growth and expansion, technological change and our exposure to market risks. By their nature, these expectations and projections are only estimates and could be materially different from actual results in the future.



Registered Office: Unichem Bhavan, Prabhat Estate, Off S. V. Road Jogeshwari (West), Mumbai – 400 102, Maharashtra, India. Tel.: +91 (22) 66888333 • Fax.: +91 (22) 26784391 • Website: www.unichemlabs.com • CIN: L99999MH1962PLC012451